Filter
196
Filtered Results: 196
Text search:
Bedaquiline
Featured
Recommendations
34
New Publications
54
Language
Document type
No document type
121
Guidelines
27
Studies & Reports
22
Manuals
10
Strategic & Response Plan
5
Fact sheets
5
Training Material
3
Situation Updates
3
Countries / Regions
Western and Central Europe
20
Eastern Europe
16
India
12
Germany
4
South Africa
4
Asia
3
Uganda
3
Ethiopia
3
El Salvador
2
Global
2
Latin America and the Carribbean
2
South–East Asia Region
2
Eastern Europe and Central Asia
2
Bolivia
2
Argentina
2
Russia
2
Nepal
1
Kenya
1
Ukraine
1
Nigeria
1
Estonia
1
Malawi
1
Philippines
1
Dominican Republic
1
Paraguay
1
Bangladesh
1
Brazil
1
Namibia
1
Romania
1
Georgia
1
Botswana
1
Zambia
1
Authors & Publishers
Publication Years
Category
Countries
46
Clinical Guidelines
39
Public Health
3
Key Resources
2
Pharmacy & Technologies
2
Toolboxes
TB
146
HIV
7
Pharmacy
5
NTDs
4
AMR
4
Caregiver
3
Polio
3
Refugee
2
COVID-19
2
Conflict
1
Global Health Education
1
Interim policy guidance
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
MMWR: Recommendations and Reports / Vol. 62 / No. 9
Morbidity and Mortality Weekly Report
October 25, 2013
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
For the first time in almost 50 years there are two new drugs for the treatment of drug-resistant TB (DR-TB): bedaquiline and delamanid. There has also been increased attention given to the safety and efficacy of “re-purposed” drugs that have been widely used to treat other infections but are al...
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delama...
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer deaths than older treatments.
The meta-analysis...
Report of a mission 20–24 April 2015
